Status:
COMPLETED
Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls
Lead Sponsor:
Stanford University
Conditions:
Anal Squamous Intraepithelial Lesion (ASIL)
HPV DNA
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.
Detailed Description
IBD patients attending the Stanford Inflammatory Bowel Disease (IBD) clinic and age-matched healthy controls are screened for eligibility. Informed consent is obtained for eligible subjects. An anonym...
Eligibility Criteria
Inclusion
- All IBD patients followed in the IBD clinic and healthy controls who are greater than 18 years old
Exclusion
- History of HPV vaccination
- Pregnancy
- Other immunosuppressed states (i.e. systemic lupus erythematosus, rheumatoid arthritis, cancer, Human Immunodeficiency Virus (HIV), transplant)
- IBD patients who don't meet immunosuppression/non-immunosuppression criteria
- Inability to obtain informed consent from patient
- Previous diagnosis of ASIL or anal/rectal cancer
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2013
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT01860963
Start Date
January 1 2010
End Date
June 1 2013
Last Update
October 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Digestive Health Center
Stanford, California, United States, 94305